Medicine
Deferasirox 125 mg tablet for oral suspension
Deferasirox 125 mg tablet for oral suspension is a generic prescription medicine for oral use, made by 9 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store deferasirox tablets for oral suspension at 20°C to 25°C (68°F to 77°F)…
Key facts
- Active ingredient (INN)
- Deferasirox
- Brand
- Sold under the generic name
- Strength
- 125 mg
- Dosage form
- Tablet for oral suspension
- Route
- Oral
- Packs
- 30 tablets, 1000 tablets, 90 tablets and 16 more
- Manufacturers
- MSN LaboratoriesIndiaNovadoz PharmaceuticalsIndiaDr. Reddy's LaboratoriesIndiaAlembic PharmaceuticalsIndiaSun Pharmaceutical IndustriesIndiaAscend LaboratoriesIndiaGlenmark PharmaceuticalsIndiaBionpharmaTeva Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store deferasirox tablets for oral suspension at 20°C to 25°C (68°F to 77°F), excursions are permitted to 15°C to 30°C (59°F to 86°F). Protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V03AC03 Deferasirox
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 September 2018
- Identifiers
- RxCUI 597768, 597770, 597772DailyMed set ID dc690f20-533e-490e-b13d-143382e02351, e0726c9c-cee8-4fc1-abd1-68ad0db030dd, e365e748-4b61-94f2-fb7a-f81919eaccaa +7NDC 69452-159, 69539-021, 43598-855 +7Application ANDA210920, ANDA209878, ANDA210060 +4
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, for suspension in 1 bottle | 46708-324-30 | Alembic PharmaceuticalsIndia | 21 November 2019 |
| 30 tablet, for suspension in 1 bottle | 62332-324-30 | Alembic PharmaceuticalsIndia | 21 November 2019 |
| 30 tablet, for suspension in 1 bottle | 67877-549-30 | Ascend LaboratoriesIndia | 22 November 2019 |
| 1000 tablet, for suspension in 1 bottle | 43598-855-10 | Dr. Reddy's LaboratoriesIndia | 20 November 2019 |
| 30 tablet, for suspension in 1 bottle | 43598-855-30 | Dr. Reddy's LaboratoriesIndia | 20 November 2019 |
| 90 tablet, for suspension in 1 bottle | 43598-855-90 | Dr. Reddy's LaboratoriesIndia | 20 November 2019 |
| 90 tablet, for suspension in 1 bottle | 68462-494-90 | Glenmark PharmaceuticalsIndia | 6 January 2020 |
| 10 blister pack in 1 carton / 10 tablet, for suspension in 1 blister pack | 69539-021-06 | MSN LaboratoriesIndia | 12 February 2020 |
| 30 tablet, for suspension in 1 bottle | 69539-021-30 | MSN LaboratoriesIndia | 20 November 2019 |
| 90 tablet, for suspension in 1 bottle | 69539-021-90 | MSN LaboratoriesIndia | 20 November 2019 |
| 1000 tablet, for suspension in 1 bottle | 69539-021-99 | MSN LaboratoriesIndia | 20 November 2019 |
| 30 tablet, for suspension in 1 bottle | 72205-389-01 | Novadoz PharmaceuticalsIndia | 29 January 2026 |
| 90 tablet, for suspension in 1 bottle | 72205-389-02 | Novadoz PharmaceuticalsIndia | 29 January 2026 |
| 1000 tablet, for suspension in 1 bottle | 72205-389-03 | Novadoz PharmaceuticalsIndia | 29 January 2026 |
| 10 blister pack in 1 carton / 10 tablet, for suspension in 1 blister pack | 72205-389-05 | Novadoz PharmaceuticalsIndia | 29 January 2026 |
| 30 tablet, for suspension in 1 bottle | 62756-568-83 | Sun Pharmaceutical IndustriesIndia | 2 December 2019 |
| 60 tablet, for suspension in 1 bottle | 62756-568-86 | Sun Pharmaceutical IndustriesIndia | 2 December 2019 |
| 30 tablet, for suspension in 1 bottle | 69452-159-13 | Bionpharma | 28 September 2018 |
| 30 tablet, for suspension in 1 bottle | 0480-7011-56 | Teva Pharmaceuticals | 1 November 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Deferasirox 125 mg tablet for oral suspension.
Other strengths and forms of Deferasirox
Clinical summary
Deferasirox is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, among other approved uses. MedsAcross supplies Deferasirox for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DeferasiroxFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Exjade prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Exjade: European public assessment report (EPAR) · European Medicines Agency
- Deferasirox Accord: European public assessment report (EPAR) · European Medicines Agency
Need Deferasirox 125 mg tablet for oral suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.